Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer
10.1097/JTO.0b013e31826baf83
Saved in:
Main Authors: | Chin, L.P., Soo, R.A., Soong, R., Ou, S.-H.I. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Review |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/115550 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
FUNCTIONAL ANALYSIS OF ANAPLASTIC LYMPHOMA KINASE DURING EMBRYONIC NEUROGENESIS IN ZEBRAFISH
by: YAO SHENG
Published: (2013) -
Characteristics and prognosis of KI-1 positive anaplastic large cell lymphoma in Asians
by: Lee, S.-C., et al.
Published: (2012) -
ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway
by: Ou, S.-H.I., et al.
Published: (2014) -
Combined temozolomide and radiation as an initial treatment for anaplastic glioma
by: Tham, C.K., et al.
Published: (2016) -
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
by: Prutsch, N, et al.
Published: (2021)